Journal Logo

June 2019 - Volume 3 - Supplement 1
pp: 1-1084

Indolent and mantle-cell non-Hodgkin lymphoma - Clinical


POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIALS102

Abrisqueta, P.; Kahl, B.; Banerjee, L.; More

HemaSphere. 3:2-3, June 2019.

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIALS103

Legouill, S.; Beldi-Ferchiou, A.; Cacheux, V.; More

HemaSphere. 3:3, June 2019.

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIALS104

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3:3, June 2019.

Novel agents and therapies for CLL


GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITYS105

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3:4, June 2019.

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIALS106

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3:4-5, June 2019.

SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): SECOND INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIALS108

Kater, A. P.; Dubois, J.; Kersting, S.; More

HemaSphere. 3:6, June 2019.

Acute myeloid leukemia - Biology & translational research - Genes and regulation


GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIAS113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

Alternative donor transplantation


POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMTS114

Nagler, A.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9, June 2019.

IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORDS115

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9-10, June 2019.

New biological and translational insights into MM


SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTESS121

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3:12-13, June 2019.

Mechanisms and strategies to address TKI resistance and stem cell persistence


SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETEDS123

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3:13-14, June 2019.

Modeling and therapeutic targeting in acute lymphoblastic leukemia I


Molecular Implications in MDS


NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMSS135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

Hematopoiesis, stem cells and microenvironment


Advances in the management of thalassemia


CLINICAL OUTCOMES OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT β-THALASSAEMIA (TDT) FOLLOWING COMPLETION OF THE NORTHSTAR (HGB-204) STUDYS141

Walters, M. C.; Kwiatkowski, J. L.; Rasko, J. E.J.; More

HemaSphere. 3:22, June 2019.

A MULTICENTRE, RANDOMIZED, NON-INFERIORITY TRIAL COMPARING THE EFFICACY OF DEFERIPRONE VERSUS DEFERASIROX IN PEDIATRIC PATIENTS AFFECTED BY TRANSFUSION-DEPENDENT HEMOGLOBINOPATHIES (DEEP-2 TRIAL)S144

Kattamis, A.; Felisi, M.; Reggiardo, G.; More

HemaSphere. 3:23-24, June 2019.


Best abstracts


PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTSS145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASES147

Vichinsky, E.; Hoppe, C. C.; Ataga, K. I.; More

HemaSphere. 3:25-26, June 2019.

FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIESS149

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3:26-27, June 2019.


Acute lymphoblastic leukemia - Biology & translational research


RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALLPF151

Laurent, A. P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3:28, June 2019.

®PF155

Lukic, Slavkovic D.; Duell, J.; Davidson-Moncada, J.; More

HemaSphere. 3:29-30, June 2019.

TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520PF158

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3:31, June 2019.

Acute lymphoblastic leukemia - Clinical


PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTSPF172

Soverini, S.; Martelli, M.; Bavaro, L.; More

HemaSphere. 3:37-38, June 2019.

MULTICENTRE STANDARDIZATION OF MINIMAL RESIDUAL DISEASE DETECTION AND QUANTITATION USING THE EUROCLONALITY-NGS ASSAYPF175

Svaton, M.; Fronkova, E.; Kotrova, M.; More

HemaSphere. 3:39-40, June 2019.

MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIAPF176

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3:40-41, June 2019.

CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL)PF182

Ribera, J. M.; García-Calduch, O.; Gil, C.; More

HemaSphere. 3:43, June 2019.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPYPF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

RECLASSIFICATION OF BIPHENOTYPIC ACUTE LEUKEMIA INTO MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO WHO CRITERIA REFINES PATIENT CHARACTERIZATION AND PROGNOSIS; DISEASE MARKERS AND IMPACT ON OUTCOMEPF191

Douka, V.; Kotta, K.; Chatziioannidis, A.; More

HemaSphere. 3:47-48, June 2019.

Acute myeloid leukemia - Biology & translational research


A NEW CLASSIFICATION OF ACUTE MYELOID LEUKEMIA BASED ON INTEGRATED GENOMICS AND METABOLOMICSPF197

Simonetti, G.; Padella, A.; Mengucci, C.; More

HemaSphere. 3:51, June 2019.

Show: